Lexicon Pharmaceuticals | LXRX - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Abbott USD 2.39B 27M 2026-03
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
AstraZeneca USD 4.81B 894M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Illumina USD 260M 103M 2026-06
Insmed USD -162.1M 164.84M 2026-03
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
J&J USD 8.66B 839M 2026-06
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
MacroGenics USD -36.77M 21.84M 2026-03
MannKind USD -16.37M 4.56M 2026-03
Merck USD 3.42B 3.32B 2025-12
Moderna USD -1.33B 535M 2026-03
Novartis USD 4.27B 430M 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Thermo Fisher Scientific USD 1.73B 389M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
United Therapeutics USD 444M 6M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12